Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume – Here’s Why

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) saw an uptick in trading volume on Friday . 140,901 shares were traded during mid-day trading, a decline of 40% from the previous session’s volume of 235,081 shares.The stock last traded at $10.51 and had previously closed at $9.80.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TLX. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Tuesday. Wedbush reiterated an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Tuesday. Finally, Wall Street Zen lowered Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Telix Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $21.13.

Telix Pharmaceuticals Price Performance

The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The stock has a 50 day moving average price of $7.83 and a two-hundred day moving average price of $8.73.

Telix Pharmaceuticals (NASDAQ:TLX) last announced its earnings results on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The firm had revenue of $206.72 million during the quarter, compared to the consensus estimate of $421.50 million. Equities analysts anticipate that Telix Pharmaceuticals Limited will post 0.24 earnings per share for the current year.

Institutional Trading of Telix Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers increased its stake in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after buying an additional 1,392 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Telix Pharmaceuticals in the fourth quarter valued at $89,000. OLD Mission Capital LLC acquired a new stake in shares of Telix Pharmaceuticals in the fourth quarter valued at $111,000. Vident Advisory LLC acquired a new stake in shares of Telix Pharmaceuticals in the fourth quarter valued at $204,000. Finally, IHT Wealth Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.